FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012258768> ?p ?o ?g. }

• W3012258768 abstract "8053 Background: Lenalidomide (LEN) is an immunomodulatory agent that has shown significant single-agent anti-lymphoma activity in patients with relapsed disease and in combination may enhance the efficacy of rituximab by various mechanisms. There is limited data on the role of LEN in combination regimens for treatment-naïve patients. This phase II single arm trial was designed to evaluate tumor response, toxicity (AE) and survival with a combination of LEN, rituximab, cyclophosphamide (CTX) and dexamethasone (DEX) (LR-CD) in symptomatic untreated patients with low grade B-cell non-Hodgkin lymphoma. Methods: Eligibility required age ≥18, ECOG PS ≤2, confirmed diagnosis of low-grade B-cell lymphoma (FL1-2, SLL, MZL or LPL/WM), measurable nodes ≥2cm or IgM ≥400mg/dL(LPL/WM), ANC ≥1400/mm 3 , platelets ≥100,000/mm 3 , creatinine ≤2mg/dL, signed informed consent and in need of therapy. Treatment consisted of IV rituximab 375mg/m 2 D1, oral LEN 20mg D1-21, CTX 250mg/m 2 D1, 8, 15, DEX 40mg D1, 8, 15, 22 and ASA 325 mg daily in a 28 day cycle. Treatment continued 2 cycles beyond best response (max 12). Toxicity was assessed by NCI CTCAE v3.0. Results: 28 patients have enrolled at Mayo Clinic with 25 evaluable for toxicity and 21 for response: Median age 65(43-83), 72% male, FL 24%, MZL 28%, LPL/WM 38%, and SLL 4%. Median number of cycles given was 5. Overall response in 21 patients with response data is 95% (95% CI 76-100%) with 19% CR (95% CI 5-42%), and 76% PR (confirmed and unconfirmed, 95% CI 53-92%). The ORR in 8 patients with LPL/WM with response data was 88%, all PR (95% CI 47-100%). At a median f/u of 14.7 months 96% are alive without progression. 1 death (unrelated) occurred 7.7 months after completing 12 cycles of treatment. The most common grade ≥3 AEs were neutropenia (37.5%), leukopenia (16.7%), anemia (12.5%) and fatigue (12.5%). Conclusions: The combination LR-CD with the novel agent LEN is feasible, well tolerated and produces high response rates in symptomatic patients with low grade B-cell NHL. Toxicities are manageable and similar to reported data of single agent LEN." @default.
• W3012258768 created "2020-03-23" @default.
• W3012258768 creator A5004152557 @default.
• W3012258768 creator A5008098486 @default.
• W3012258768 creator A5027394636 @default.
• W3012258768 creator A5033991135 @default.
• W3012258768 creator A5039064680 @default.
• W3012258768 creator A5045418082 @default.
• W3012258768 creator A5048185910 @default.
• W3012258768 creator A5050306435 @default.
• W3012258768 creator A5055454241 @default.
• W3012258768 creator A5059729547 @default.
• W3012258768 creator A5059956607 @default.
• W3012258768 creator A5061713890 @default.
• W3012258768 creator A5087950597 @default.
• W3012258768 creator A5090009905 @default.
• W3012258768 date "2012-05-20" @default.
• W3012258768 modified "2023-09-28" @default.
• W3012258768 title "LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL." @default.
• W3012258768 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.8053" @default.
• W3012258768 hasPublicationYear "2012" @default.
• W3012258768 type Work @default.
• W3012258768 sameAs 3012258768 @default.
• W3012258768 citedByCount "0" @default.
• W3012258768 crossrefType "journal-article" @default.
• W3012258768 hasAuthorship W3012258768A5004152557 @default.
• W3012258768 hasAuthorship W3012258768A5008098486 @default.
• W3012258768 hasAuthorship W3012258768A5027394636 @default.
• W3012258768 hasAuthorship W3012258768A5033991135 @default.
• W3012258768 hasAuthorship W3012258768A5039064680 @default.
• W3012258768 hasAuthorship W3012258768A5045418082 @default.
• W3012258768 hasAuthorship W3012258768A5048185910 @default.
• W3012258768 hasAuthorship W3012258768A5050306435 @default.
• W3012258768 hasAuthorship W3012258768A5055454241 @default.
• W3012258768 hasAuthorship W3012258768A5059729547 @default.
• W3012258768 hasAuthorship W3012258768A5059956607 @default.
• W3012258768 hasAuthorship W3012258768A5061713890 @default.
• W3012258768 hasAuthorship W3012258768A5087950597 @default.
• W3012258768 hasAuthorship W3012258768A5090009905 @default.
• W3012258768 hasConcept C126322002 @default.
• W3012258768 hasConcept C143998085 @default.
• W3012258768 hasConcept C2776063141 @default.
• W3012258768 hasConcept C2776364478 @default.
• W3012258768 hasConcept C502942594 @default.
• W3012258768 hasConcept C71924100 @default.
• W3012258768 hasConceptScore W3012258768C126322002 @default.
• W3012258768 hasConceptScore W3012258768C143998085 @default.
• W3012258768 hasConceptScore W3012258768C2776063141 @default.
• W3012258768 hasConceptScore W3012258768C2776364478 @default.
• W3012258768 hasConceptScore W3012258768C502942594 @default.
• W3012258768 hasConceptScore W3012258768C71924100 @default.
• W3012258768 hasLocation W30122587681 @default.
• W3012258768 hasOpenAccess W3012258768 @default.
• W3012258768 hasPrimaryLocation W30122587681 @default.
• W3012258768 hasRelatedWork W1489641321 @default.
• W3012258768 hasRelatedWork W2093121143 @default.
• W3012258768 hasRelatedWork W2100645234 @default.
• W3012258768 hasRelatedWork W2163393078 @default.
• W3012258768 hasRelatedWork W2165912411 @default.
• W3012258768 hasRelatedWork W2297917740 @default.
• W3012258768 hasRelatedWork W2466693085 @default.
• W3012258768 hasRelatedWork W2514819561 @default.
• W3012258768 hasRelatedWork W2536534414 @default.
• W3012258768 hasRelatedWork W2562570034 @default.
• W3012258768 hasRelatedWork W2567077644 @default.
• W3012258768 hasRelatedWork W2569660516 @default.
• W3012258768 hasRelatedWork W2599169200 @default.
• W3012258768 hasRelatedWork W2600808378 @default.
• W3012258768 hasRelatedWork W2602729549 @default.
• W3012258768 hasRelatedWork W2988081634 @default.
• W3012258768 hasRelatedWork W2991945103 @default.
• W3012258768 hasRelatedWork W3088845964 @default.
• W3012258768 hasRelatedWork W3208807022 @default.
• W3012258768 hasRelatedWork W2783054148 @default.
• W3012258768 isParatext "false" @default.
• W3012258768 isRetracted "false" @default.
• W3012258768 magId "3012258768" @default.
• W3012258768 workType "article" @default.